Dr. Kelvin Cooper is a seasoned pharmaceutical scientist and executive with more than 45 years’ experience in all aspects of drug discovery and development across a range of therapeutic areas including infectious disease, cancer, respiratory and immunology/inflammation.

Most recently Dr. Cooper was an independent consultant with KC Pharma Consulting in areas such as portfolio analysis, process analysis, organizational analysis, software development and the interface between Artificial Intelligence and Drug Discovery.

Prior to that Dr. Cooper worked at Pfizer in several roles including Senior Vice President for portfolio development in the Established Products Business Unit, where he was responsible for expanding the portfolio of established products from 350 to 500 medicines, including the first orphan drug in-licensed by Pfizer – Uplyso from Protalix. Prior to that his roles included Senior Vice President of Worldwide Pharmaceutical Sciences with responsibility for both small molecules and biologics in the areas of drug substance, drug product and device development; Executive Director of drug development for cancer, respiratory, allergy, immunology and infectious disease; and Director of drug discovery in those same therapeutic areas. Two key drugs that emerged from this discovery and development portfolio were the launched medicines Tarceva® and Tofacitinib.

Dr. Cooper earned a PhD in Organic Chemistry from the University of Nottingham, UK in 1982 and was awarded the Captain Black Award for Science. He has 46 publications and 34 patents.